Mad Money w/ Jim Cramer

Jim Cramer dives into the shifting dynamics of Wall Street, contrasting index gains with stock picking strategies. He discusses the shrinking price-to-earnings ratios among major players and highlights a surge in money flow into storage and semiconductor stocks. The impact of AI on enterprise software raises concerns, while Cramer previews earnings for Procter & Gamble and 3M, shedding light on operational changes. The Lightning Round features rapid-fire stock picks, and Cramer emphasizes the psychological factors influencing stock movements during earnings season.

Joe Wolk, Chief Financial Officer of Johnson & Johnson, shares insights into the company’s recent earnings and optimistic guidance for the future. He discusses impressive growth in pharmaceuticals and MedTech, as well as new vision care technologies. Wolk highlights J&J’s strategic acquisitions, particularly in cardiovascular sectors, and the promising prospects of Kapilita in neuroscience. They also touch on how current U.S. policies are supporting life sciences investments, along with J&J's robust defense against litigation.

Join Jim Cramer as he navigates the wild world of Wall Street! He breaks down the market sell-off driven by tariff threats and discusses the importance of taking profits on speculative stocks. Discover the risks of heavy tech exposure and the need for diversification. Cramer offers sage advice on precious metals and critiques the frenzy in sectors like energy and crypto. Plus, hear his lightning-fast responses to listener calls and a checklist of macro risks that could shake the market. Stay informed and ready to act!

Jim dives into the complexities of Wall Street, offering insights on market trends and key earnings reports. He highlights the potential of D.R. Horton amid housing price fluctuations and shares his thoughts on travel stocks like United and Marriott. Cramer also examines the implications of inflation on investments, champions several tech companies, and discusses the challenges facing 3M and GE Aerospace. With advice for navigating volatility through a diversified portfolio, Jim urges caution while seeking the next big opportunities.

Bipul Sinha, Co-founder and CEO of Rubrik, joins to share insights into the booming data security sector. He discusses how Rubrik is leading the charge in data recovery and cybersecurity solutions. Sinha highlights impressive growth metrics and the importance of agentic AI governance in enhancing resilience. The conversation touches on free cash flow improvements, positioning Rubrik as a formidable player in an increasingly digital world. This deep dive into cybersecurity is both insightful and timely for investors.

Dr. Vlad Schorch, a biotech executive and CEO of Biohaven, discusses groundbreaking advancements in neuroscience and immunology. He shares insights into the company's endeavors in tackling obesity and epilepsy through innovative treatments. The conversation highlights recent clinical developments and financial strategies that showcase Biohaven's resilience in a competitive landscape. Jim Cramer and Dr. Schorch dive into the future potential of precision medicine, making complex topics engaging and accessible.

In this episode, Jim Cramer sits down with several industry leaders. Dr. Vass Nairosif, CEO of Novartis, shares insights on portfolio simplification and the future of radioligand therapy. Robert Bradway from Amgen discusses his company's innovative obesity drug, highlighting long-term efficacy. Dr. Leonard Schleifer of Regeneron talks about groundbreaking treatments like Dupixent and their advancements in cardiovascular risk. Jason Holler of Cardinal Health explores operational improvements and specialty distribution, emphasizing a strong financial outlook.

Mike Deustar, President and CEO of Novo Nordisk, dives into the groundbreaking launch of their oral GLP-1 pill, addressing its cardiovascular benefits and pricing strategies. Jeff Marthin, CEO of Medtronic, shares insights on innovative FDA-approved devices like the smart glucose pen and the company's ambitious diabetes spin-off plans. Albert Borla, Chairman of Pfizer, explores their weight-loss initiatives and acquisition strategies amid looming loss of exclusivity. Finally, Brent Saunders, CEO of Bausch & Lomb, reveals exciting advancements in eye care and a robust growth plan.

Navigate the chaotic world of Wall Street with insights on the Magnificent Seven stocks and a buy-and-hold strategy. Discover key events shaping market directions, including the JPMorgan Healthcare Conference and CPI data. Jim Cramer shares advice on trading banks and delves into the transport sector's improving trends. Hear recommendations on Cloudflare and Cheesecake Factory, alongside a deep dive into Shark Ninja's comeback. Plus, explore the implications of ongoing M&A buzz in biotech and the energy landscape with Venezuela's reopening.

Jim Cramer tackles January's market volatility and highlights sector rotations with intriguing stock comparisons. He contrasts the performance of Constellation Energy and Constellation Brands, delves into Costco vs. Walmart's valuation trends, and discusses Nike's management changes amid insider buying. Cramer identifies winning sectors in 2025, especially in communication services and industrials. He offers insights into real estate weaknesses and gives listeners a rapid-fire guide during the Lightning Round, all while contextualizing presidential market interventions.